RYTM Rhythm Pharmaceuticals
- 38.500
- -0.420-1.08%
Rhythm Pharmaceuticals News
Press Release: Rhythm Pharmaceuticals Announces New Employment Inducement Grants
Rhythm Pharmaceuticals Announces New Employment Inducement Grants BOSTON, May 09, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company fo
Anti-Obesity Drugs Global Strategic Business Report 2024-2030 Featuring F. Hoffmann-La Roche, GlaxoSmithKline, Eisai, Novo Nordisk, Rhythm Pharmaceuticals, and VIVUS - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--The "Anti-Obesity Drugs - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.Global Anti-Obesity Drugs Market to Reach $4.8 Billion b
Rhythm Pharmaceuticals Is Maintained at Buy by Canaccord Genuity
Rhythm Pharmaceuticals Is Maintained at Buy by Canaccord Genuity
Rhythm Pharmaceuticals Price Target Cut to $79.00/Share From $80.00 by Canaccord Genuity
Rhythm Pharmaceuticals Price Target Cut to $79.00/Share From $80.00 by Canaccord Genuity
Canaccord Genuity Maintains Buy on Rhythm Pharmaceuticals, Lowers Price Target to $79
Canaccord Genuity analyst Whitney Ijem maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Buy and lowers the price target from $80 to $79.
Maintaining Buy Rating on Rhythm Pharmaceuticals: Positive Outlook Amidst Growth and Upcoming Catalysts
BofA Downgrades Rhythm Pharmaceuticals to Neutral From Buy, Adjusts Price Target to $42 From $49
09:52 AM EDT, 05/08/2024 (MT Newswires) -- BofA Downgrades Rhythm Pharmaceuticals to Neutral From Buy, Adjusts Price Target to $42 From $49 Price: 37.98, Change: -1.37, Percent Change: -3.48
Earnings Call Summary | Rhythm Pharmaceuticals(RYTM.US) Q1 2024 Earnings Conference
The following is a summary of the Rhythm Pharmaceuticals, Inc (RYTM) Q1 2024 Earnings Call Transcript:Financial Performance:Rhythm reported Q1 revenue of $26 million, with a 7% increase from Q4 and mo
Rhythm Pharmaceuticals: A Strong Buy on Robust Q1 Performance and Promising Clinical Catalysts
Rhythm Pharmaceuticals Price Target Cut to $42.00/Share From $49.00 by B of A Securities
Rhythm Pharmaceuticals Price Target Cut to $42.00/Share From $49.00 by B of A Securities
Rhythm Pharmaceuticals Cut to Neutral From Buy by B of A Securities
Rhythm Pharmaceuticals Cut to Neutral From Buy by B of A Securities
B of A Securities Downgrades Rhythm Pharmaceuticals to Neutral, Lowers Price Target to $42
B of A Securities analyst Tazeen Ahmad downgrades Rhythm Pharmaceuticals from Buy to Neutral and lowers the price target from $49 to $42.
Rhythm Pharmaceuticals Inc (RYTM) Q1 2024 Earnings Call Transcript Highlights: A Detailed ...
Express News | Rhythm Pharmaceuticals Inc : Needham Cuts Target Price to $46 From $50
Rhythm Pharmaceuticals | 10-Q: Quarterly report
Rhythm Pharmaceuticals Is Maintained at Buy by Needham
Rhythm Pharmaceuticals Is Maintained at Buy by Needham
Express News | Needham Maintains Buy on Rhythm Pharmaceuticals, Lowers Price Target to $46
Rhythm Pharmaceuticals Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/07/2024 20.26% Needham $50 → $46 Maintains Buy 04/26/2024 30.72% Needham → $50 Reiterates Buy → Buy 04/
Buy Rating Affirmed for Rhythm Pharmaceuticals Amid Positive Prescription Growth and Pipeline Potential
Rhythm Pharmaceuticals Down Over 13%, on Pace for Largest Percent Decrease Since September 2022 -- Data Talk
Rhythm Pharmaceuticals, Inc. (RYTM) is currently at $38.15, down $5.73 or 13.06% --Would be lowest close since April 25, 2024, when it closed at $38.15 --On pace for largest percent decrease since S
Analysis
Price Target
No Data
